Dimensional Fund Advisors LP Buys 105,288 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Dimensional Fund Advisors LP boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 9.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,198,590 shares of the company’s stock after purchasing an additional 105,288 shares during the period. Dimensional Fund Advisors LP owned about 2.49% of Amphastar Pharmaceuticals worth $44,503,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. First Trust Advisors LP lifted its position in shares of Amphastar Pharmaceuticals by 350.0% during the 4th quarter. First Trust Advisors LP now owns 81,129 shares of the company’s stock valued at $3,012,000 after buying an additional 63,100 shares in the last quarter. Marshall Wace LLP raised its stake in Amphastar Pharmaceuticals by 7.1% during the 4th quarter. Marshall Wace LLP now owns 608,706 shares of the company’s stock worth $22,601,000 after acquiring an additional 40,212 shares during the period. Walleye Capital LLC purchased a new position in Amphastar Pharmaceuticals during the fourth quarter valued at approximately $322,000. Barclays PLC boosted its position in shares of Amphastar Pharmaceuticals by 13.9% in the fourth quarter. Barclays PLC now owns 84,790 shares of the company’s stock worth $3,148,000 after purchasing an additional 10,334 shares during the period. Finally, Bessemer Group Inc. increased its stake in shares of Amphastar Pharmaceuticals by 2.4% in the fourth quarter. Bessemer Group Inc. now owns 488,630 shares of the company’s stock worth $18,144,000 after purchasing an additional 11,609 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMPH. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.

Insiders Place Their Bets

In related news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 5,231 shares of company stock worth $142,752 in the last 90 days. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $24.50 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company’s fifty day moving average price is $26.32 and its 200-day moving average price is $35.66. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The company has a market capitalization of $1.16 billion, a PE ratio of 8.17, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.